相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Dabrafenib plus trametinib in patients with BRAFV600E-mutant low-grade and high-grade glioma (ROAR): a multicentre, open-label, single-arm, phase 2, basket trial
Patrick Y. Wen et al.
LANCET ONCOLOGY (2022)
Prevalence of BRAFV600 in glioma and use of BRAF Inhibitors in patients with BRAFV600 mutation-positive glioma: systematic review
Lily J. Andrews et al.
NEURO-ONCOLOGY (2022)
HSP90 Inhibition Overcomes Resistance to Molecular Targeted Therapy in BRAFV600E-mutant High-grade Glioma
Jo Sasame et al.
CLINICAL CANCER RESEARCH (2022)
Genetic Characteristics Associated With Drug Resistance in Lung Cancer and Colorectal Cancer Using Whole Exome Sequencing of Cell-Free DNA
Jong Won Lee et al.
FRONTIERS IN ONCOLOGY (2022)
Mechanistic and Clinical Overview Cardiovascular Toxicity of BRAF and MEK Inhibitors JACC: CardioOncology State-of-the-Art Review
Claire Glen et al.
JACC: CARDIOONCOLOGY (2022)
Primary analysis of a phase II trial of dabrafenib plus trametinib (dab + tram) in BRAF V600–mutant pediatric low-grade glioma (pLGG).
Eric Bouffet et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
FIREFLY-1 (PNOC 026): A phase 2 study to evaluate the safety and efficacy of tovorafenib (DAY101) in pediatric patients with RAF-altered recurrent or progressive low-grade glioma or advanced solid tumors.
Daniel B Landi et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Resistance mechanisms to targeted therapy in BRAF-mutant melanoma - A mini review
Lokeswari P. Tangella et al.
BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS (2021)
Identification of resistance pathways and therapeutic targets in relapsed multiple myeloma patients through single-cell sequencing
Yael C. Cohen et al.
NATURE MEDICINE (2021)
BRAF paradox breakers PLX8394, PLX7904 are more effective against BRAFV600E CRC cells compared with the BRAF inhibitor PLX4720 and shown by detailed pathway analysis
Kassandra Koumaki et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE (2021)
Deconvoluting Mechanisms of Acquired Resistance to RAF Inhibitors in BRAFV600E-Mutant Human Glioma
Karisa C. Schreck et al.
CLINICAL CANCER RESEARCH (2021)
Drug resistance in targeted cancer therapies with RAF inhibitors
Ufuk Degirmenci et al.
CANCER DRUG RESISTANCE (2021)
Long-term outcomes in patients with BRAF V600-mutant metastatic melanoma receiving dabrafenib monotherapy: Analysis from phase 2 and 3 clinical trials
Axel Hauschild et al.
EUROPEAN JOURNAL OF CANCER (2020)
Phase I study of vemurafenib in children with recurrent or progressive BRAFV600E mutant brain tumors: Pacific Pediatric Neuro-Oncology Consortium study (PNOC-002)
Theodore Nicolaides et al.
Oncotarget (2020)
Pediatric low-grade glioma in the era of molecular diagnostics
Scott Ryall et al.
ACTA NEUROPATHOLOGICA COMMUNICATIONS (2020)
Trametinib for the treatment of recurrent/progressive pediatric low-grade glioma
Neevika Manoharan et al.
JOURNAL OF NEURO-ONCOLOGY (2020)
Response to trametinib treatment in progressive pediatric low-grade glioma patients
Florian Selt et al.
JOURNAL OF NEURO-ONCOLOGY (2020)
Outcomes of BRAF V600E Pediatric Gliomas Treated With Targeted BRAF Inhibition
Liana Nobre et al.
JCO PRECISION ONCOLOGY (2020)
Dual inhibition of BRAF and mTOR in BRAFV600E-mutant pediatric, adolescent, and young adult brain tumors
Shiraj Sen et al.
COLD SPRING HARBOR MOLECULAR CASE STUDIES (2020)
CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2013-2017
Quinn T. Ostrom et al.
NEURO-ONCOLOGY (2020)
Loss of BOP1 confers resistance to BRAF kinase inhibitors in melanoma by activating MAP kinase pathway
Romi Gupta et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2019)
Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial
Jason Fangusaro et al.
LANCET ONCOLOGY (2019)
Diverse Mechanisms of BRAF Inhibitor Resistance in Melanoma Identified in Clinical and Preclinical Studies
Stephen A. Luebker et al.
FRONTIERS IN ONCOLOGY (2019)
Mapping phospho-catalytic dependencies of therapy-resistant tumours reveals actionable vulnerabilities
Jean-Philippe Coppe et al.
NATURE CELL BIOLOGY (2019)
Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma
C. Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
A view on drug resistance in cancer
Neil Vasan et al.
NATURE (2019)
Efficacy and Safety of Dabrafenib in Pediatric Patients with BRAF V600 Mutation-Positive Relapsed or Refractory Low-Grade Glioma: Results from a Phase I/IIa Study
Darren R. Hargrave et al.
CLINICAL CANCER RESEARCH (2019)
A Secondary Mutation in BRAF Confers Resistance to RAF Inhibition in a BRAFV600E-Mutant Brain Tumor
Jiawan Wang et al.
CANCER DISCOVERY (2018)
BRAF Inhibition in BRAFV600-Mutant Gliomas: Results From the VE-BASKET Study
Thomas Kaley et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
LOW GRADE GLIOMA CLINIC - ESTABLISHING AN INNOVATIVE SERVICE BASED ON A MULTIDISCIPLINARY APPROACH
José Pedro Lavrador et al.
NEURO-ONCOLOGY (2018)
Acquired resistance to BRAF inhibition in RAFV600E mutant gliomas
Tsun-Wen Yao et al.
ONCOTARGET (2017)
Co-occurring Genomic Alterations and Association With Progression-Free Survival in BRAFV600-Mutated Nonmelanoma Tumors
Shiraj Sen et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2017)
Targeted MAPK Pathway Inhibitors in Patients With Disseminated Pilocytic Astrocytomas
Anastasia Drobysheva et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2017)
A phase I trial of the MEK inhibitor selumetinib (AZD6244) in pediatric patients with recurrent or refractory low-grade glioma: a Pediatric Brain Tumor Consortium (PBTC) study
Anuradha Banerjee et al.
NEURO-ONCOLOGY (2017)
A Phase Ib Dose-Escalation Study of Encorafenib and Cetuximab with or without Alpelisib in Metastatic BRAF-Mutant Colorectal Cancer
Robin M. J. M. van Geel et al.
CANCER DISCOVERY (2017)
Co-occurring Genomic Alterations and Association With Progression-Free Survival in BRAFV600-Mutated Nonmelanoma Tumors
Shiraj Sen et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2017)
New perspectives for targeting RAF kinase in human cancer
Zoi Karoulia et al.
NATURE REVIEWS CANCER (2017)
The Different Mechanisms of Cancer Drug Resistance: A Brief Review
Behzad Mansoori et al.
ADVANCED PHARMACEUTICAL BULLETIN (2017)
B-Raf Inhibition in the Clinic: Present and Future
Warren Fiskus et al.
ANNUAL REVIEW OF MEDICINE, VOL 67 (2016)
An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling
Zoi Karoulia et al.
CANCER CELL (2016)
An Atlas of the Human Kinome Reveals the Mutational Landscape Underlying Dysregulated Phosphorylation Cascades in Cancer
Aleksandra Olow et al.
CANCER RESEARCH (2016)
Vemurafenib in patients with BRAFV600E-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial
Marcia S. Brose et al.
LANCET ONCOLOGY (2016)
Dabrafenib plus trametinib in patients with previously treated BRAFV600E-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial
David Planchard et al.
LANCET ONCOLOGY (2016)
Loss of cohesin complex components STAG2 or STAG3 confers resistance to BRAF inhibition in melanoma
Che-Hung Shen et al.
NATURE MEDICINE (2016)
Profound clinical and radiological response to BRAF inhibition in a 2-month-old diencephalic child with hypothalamic/chiasmatic glioma
Alvaro Lassaletta et al.
PEDIATRIC BLOOD & CANCER (2016)
BRAF Mutation and CDKN2A Deletion Define a Clinically Distinct Subgroup of Childhood Secondary High-Grade Glioma
Matthew Mistry et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Next-generation (epi)genetic drivers of childhood brain tumours and the outlook for targeted therapies
Paul A. Northcott et al.
LANCET ONCOLOGY (2015)
Regulation of RAF protein kinases in ERK signalling
Hugo Lavoie et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2015)
EGFR blockade prevents glioma escape from BRAFV600E targeted therapy
Tsun-Wen Yao et al.
ONCOTARGET (2015)
Role of P-Glycoprotein on the Brain Penetration and Brain Pharmacodynamic Activity of the MEK Inhibitor Cobimetinib
Edna F. Choo et al.
MOLECULAR PHARMACEUTICS (2014)
Phase II study of sorafenib in children with recurrent or progressive low-grade astrocytomas
Matthias A. Karajannis et al.
NEURO-ONCOLOGY (2014)
Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma
G. V. Long et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Resistance to vemurafenib resulting from a novel mutation in the BRAFV600E kinase domain
Timothy R. Wagenaar et al.
PIGMENT CELL & MELANOMA RESEARCH (2014)
Vemurafenib in Pediatric Patients With BRAFV600E Mutated High-Grade Gliomas
Francisco Bautista et al.
PEDIATRIC BLOOD & CANCER (2014)
Feedback and redundancy in receptor tyrosine kinase signaling: relevance to cancer therapies
Chong Sun et al.
TRENDS IN BIOCHEMICAL SCIENCES (2014)
Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond
Matthew Holderfield et al.
NATURE REVIEWS CANCER (2014)
BRAF Inhibition Is Associated with Enhanced Melanoma Antigen Expression and a More Favorable Tumor Microenvironment in Patients with Metastatic Melanoma
Dennie T. Frederick et al.
CLINICAL CANCER RESEARCH (2013)
Brainstem Ganglioglioma Successfully Treated With Vemurafenib
Sarah Rush et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
B-Raf and the inhibitors: from bench to bedside
Tiangui Huang et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2013)
Tumor adaptation and resistance to RAF inhibitors
Piro Lito et al.
NATURE MEDICINE (2013)
Paradoxical activation and RAF inhibitor resistance of BRAF protein kinase fusions characterizing pediatric astrocytomas
Angela J. Sievert et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Concurrent MEK2 Mutation and BRAF Amplification Confer Resistance to BRAF and MEK Inhibitors in Melanoma
Jessie Villanueva et al.
CELL REPORTS (2013)
Vemurafenib enhances MHC induction in BRAFV600E homozygous melanoma cells
Bishu Sapkota et al.
ONCOIMMUNOLOGY (2013)
Mechanisms Limiting Distribution of the Threonine-Protein Kinase B-RaFV600E Inhibitor Dabrafenib to the Brain: Implications for the Treatment of Melanoma Brain Metastases
Rajendar K. Mittapalli et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2013)
MAPK pathway activation in pilocytic astrocytoma
David T. W. Jones et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2012)
Selective BRAF Inhibitors Induce Marked T-cell Infiltration into Human Metastatic Melanoma
James S. Wilmott et al.
CLINICAL CANCER RESEARCH (2012)
Restricted brain penetration of the tyrosine kinase inhibitor erlotinib due to the drug transporters P-gp and BCRP
Nienke A. de Vries et al.
INVESTIGATIONAL NEW DRUGS (2012)
Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial
Gerald S. Falchook et al.
LANCET (2012)
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
Axel Hauschild et al.
LANCET (2012)
Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion
Ravid Straussman et al.
NATURE (2012)
Impact of P-Glycoprotein (ABCB1) and Breast Cancer Resistance Protein (ABCG2) on the Brain Distribution of a Novel BRAF Inhibitor: Vemurafenib (PLX4032)
Rajendar K. Mittapalli et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2012)
Resistance to BRAF Inhibitors: Unraveling Mechanisms and Future Treatment Options
Jessie Villanueva et al.
CANCER RESEARCH (2011)
BRAFV600E: Implications for Carcinogenesis and Molecular Therapy
Emma R. Cantwell-Dorris et al.
MOLECULAR CANCER THERAPEUTICS (2011)
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
Paul B. Chapman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Estimates of cancer incidence and mortality in Europe in 2008
J. Ferlay et al.
EUROPEAN JOURNAL OF CANCER (2010)
RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF
Poulikos I. Poulikakos et al.
NATURE (2010)
Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma
Gideon Bollag et al.
NATURE (2010)
COT drives resistance to RAF inhibition through MAP kinase pathway reactivation
Cory M. Johannessen et al.
NATURE (2010)
P-glycoprotein and Breast Cancer Resistance Protein Influence Brain Distribution of Dasatinib
Ying Chen et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2009)
Factors underlying sensitivity of cancers to small-molecule kinase inhibitors
Pasi A. Jaenne et al.
NATURE REVIEWS DRUG DISCOVERY (2009)
Targeting cancer with small molecule kinase inhibitors
Jianming Zhang et al.
NATURE REVIEWS CANCER (2009)
Activation of tyrosine kinases by mutation of the gatekeeper threonine
Mohammad Azam et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2008)
Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity
James Tsai et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
MAP kinase signalling pathways in cancer
A. S. Dhillon et al.
ONCOGENE (2007)
Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF
PTC Wan et al.
CELL (2004)
BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis
SM Wilhelm et al.
CANCER RESEARCH (2004)
Mutations of the BRAF gene in human cancer
H Davies et al.
NATURE (2002)
Molecular physiology and pathophysiology of tight junctions in the blood-brain barrier
JD Huber et al.
TRENDS IN NEUROSCIENCES (2001)
分享论文
